IBDEI0YM ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17201,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17201,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,17201,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,17201,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,17202,0)
 ;;=289.9^^111^1077^66
 ;;^UTILITY(U,$J,358.3,17202,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17202,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,17202,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,17202,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,17203,0)
 ;;=205.02^^111^1077^30
 ;;^UTILITY(U,$J,358.3,17203,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17203,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,17203,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17203,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,17204,0)
 ;;=205.12^^111^1077^16
 ;;^UTILITY(U,$J,358.3,17204,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17204,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,17204,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17204,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,17205,0)
 ;;=205.20^^111^1077^59
 ;;^UTILITY(U,$J,358.3,17205,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17205,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,17205,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,17205,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,17206,0)
 ;;=205.21^^111^1077^58
 ;;^UTILITY(U,$J,358.3,17206,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17206,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,17206,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,17206,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,17207,0)
 ;;=205.22^^111^1077^57
 ;;^UTILITY(U,$J,358.3,17207,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17207,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,17207,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,17207,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,17208,0)
 ;;=205.30^^111^1077^35
 ;;^UTILITY(U,$J,358.3,17208,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17208,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,17208,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,17208,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,17209,0)
 ;;=205.31^^111^1077^34
 ;;^UTILITY(U,$J,358.3,17209,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17209,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,17209,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,17209,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,17210,0)
 ;;=205.32^^111^1077^33
 ;;^UTILITY(U,$J,358.3,17210,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17210,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,17210,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,17210,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,17211,0)
 ;;=205.80^^111^1077^44
 ;;^UTILITY(U,$J,358.3,17211,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17211,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,17211,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,17211,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,17212,0)
 ;;=205.81^^111^1077^43
 ;;^UTILITY(U,$J,358.3,17212,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17212,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,17212,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,17212,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,17213,0)
 ;;=205.82^^111^1077^42
 ;;^UTILITY(U,$J,358.3,17213,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17213,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,17213,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,17213,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,17214,0)
 ;;=205.90^^111^1077^65
 ;;^UTILITY(U,$J,358.3,17214,1,0)
 ;;=^358.31IA^8^2
